.png)
alexsl
- Neurogene (NASDAQ:NGNE) was downgraded to Neutral from Outperform at Baird, citing increasing regulatory uncertainty and a higher approval bar at the FDA under new leadership.
- The analysts at Baird said that despite the stock rebound since April, they believe the FDA's
English (US) ·